Base de dados : MEDLINE
Pesquisa : A11.118.637.555.283.750 [Categoria DeCS]
Referências encontradas : 69 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 69 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26655741
[Au] Autor:Zhou Y; Liu JQ; Zhou ZH; Lv XT; Chen YQ; Sun LQ; Chen FX
[Ad] Endereço:Department of Central Laboratory, 97th Hospital of PLA, 226 Tongshan Road, Xuzhou 221004, China.
[Ti] Título:Enhancement of CD3AK cell proliferation and killing ability by α-Thujone.
[So] Source:Int Immunopharmacol;30:57-61, 2016 Jan.
[Is] ISSN:1878-1705
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Thujone is a monoterpene ketone natural substance found mainly in wormwood and sage. Previous studies have shown that Thujone has various pharmacological effects, such as anti-tumor, analgesic, and insecticide. The effect of α-Thujone to human immune cells is still unknown. Our study focuses on investigating the effects and mechanism of α-Thujone to CD3AK (anti- CD3 antibody induced activated killer) cells proliferation and cytotoxicity to colon cancer cell lines. With cell proliferation and FCM assay, it is found that α-Thujone could significantly enhance CD3AK cell proliferation and expression of CD107a in a dose-dependent manner. The cytotoxicity to colon cancer cells detected by CCK-8 assay is also improved. The expressions of TNF-α and FasL detected with ELISA assay were not significantly changed. Mechanically, the study shows that α-Thujone could enhance the expression of p-ERK1/2 and p-Akt. In addition, α-Thujone has no cytotoxicity to HCT116 and SW620 cells proliferation. In a word, α-Thujone enhances CD3AK cell proliferation and cytotoxicity via the improvement of expression of CD107a, p-Akt and p-ERK1/2.
[Mh] Termos MeSH primário: Vacinas Anticâncer/imunologia
Neoplasias do Colo/terapia
Imunoterapia Adotiva
Monócitos Matadores Ativados/efeitos dos fármacos
Monoterpenos/farmacologia
[Mh] Termos MeSH secundário: Anticorpos/metabolismo
Artemisia/imunologia
Complexo CD3/imunologia
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Neoplasias do Colo/imunologia
Citotoxicidade Imunológica/efeitos dos fármacos
Seres Humanos
Proteína 1 de Membrana Associada ao Lisossomo/metabolismo
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Monócitos Matadores Ativados/fisiologia
Fosforilação/efeitos dos fármacos
Proteínas Proto-Oncogênicas c-akt/genética
Proteínas Proto-Oncogênicas c-akt/metabolismo
Salvia officinalis/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies); 0 (CD3 Complex); 0 (Cancer Vaccines); 0 (Lysosomal-Associated Membrane Protein 1); 0 (Monoterpenes); 8ZI5R3T54Q (beta-thujone); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151215
[St] Status:MEDLINE


  2 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25068849
[Au] Autor:Johnson CL; Green DS; Zoon KC
[Ad] Endereço:Cytokine Biology Section, National Institute of Allergy and Infectious Diseases , National Institutes of Health, Bethesda, Maryland.
[Ti] Título:Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin.
[So] Source:J Interferon Cytokine Res;35(1):55-62, 2015 Jan.
[Is] ISSN:1557-7465
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Interferons (IFNs) play an important role in immune surveillance of tumors; however, their efficacy in the treatment of malignancies has been limited. Monocytes are mononuclear phagocytes that are critical to the generation of an innate immune response to tumors. The authors and others have shown that treatment of tumor cell lines in vitro and in vivo with human monocytes primed with type I and type II IFNs results in killing. We now expand on this work, in an extended panel of ovarian cancer cell lines. In this study, we hypothesized that there would be variable sensitivity amongst cell lines to the killing properties of monocytes and IFNs. To this end, we explored the interactions of IFN primed monocytes in conjunction with the standard of therapy for ovarian cancer, taxane, and platinum-based chemotherapeutics. Using 6 ovarian cancer cell lines, we demonstrated that there is variation from cell line to cell line in the ability of IFN-α2a and IFN-γ primed monocytes to synergistically kill target tumor cells, and further, there is an additive killing effect when target cells are treated with both IFN primed monocytes and chemotherapy.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Interferon-alfa/uso terapêutico
Interferon gama/uso terapêutico
Monócitos Matadores Ativados/imunologia
Neoplasias Ovarianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica
Carboplatina/uso terapêutico
Linhagem Celular Tumoral
Feminino
Seres Humanos
Neoplasias Ovarianas/imunologia
Paclitaxel/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., INTRAMURAL
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Interferon-alpha); 82115-62-6 (Interferon-gamma); BG3F62OND5 (Carboplatin); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140729
[St] Status:MEDLINE
[do] DOI:10.1089/jir.2014.0057


  3 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21873167
[Au] Autor:Morisaki T; Onishi H; Koya N; Kiyota A; Tanaka H; Umebayashi M; Ogino T; Nagamatsu I; Katano M
[Ad] Endereço:Fukuoka General Cancer Clinic, 3-1-1 Sumiyoshi, Hakata-ku, Fukuoka 812-0018, Japan. tmorisaki@cancer-clinic.jp
[Ti] Título:Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.
[So] Source:Anticancer Res;31(7):2505-10, 2011 Jul.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: Natural-killer group 2, member D (NKG2D) is an activating receptor on natural killer cells and activated T-cells, designated cytokine-activated killer (CAK) cells here. The MHC class I chain-related A and B (MICA and MICB, respectively) are ligands of NKG2D and are expressed on various human tumor cells, including hepatocellular carcinoma (HCC) cells. Here, we investigate whether gemcitabine, a chemotherapeutic agent, affects MICA/B expression in HCC. MATERIALS AND METHODS: We used ELISA, RT-PCR and adherent target detachment assays to determine expression of MICA/B in HepG2 HCC cells and the level of cellular cytotoxicity generated by treatment with gemcitabine and/or CAK cells. RESULTS: Surface expression of MICA/B was evident after gemcitabine treatment, and MICB-specific mRNA was up-regulated. Pre-treatment with gemcitabine and subsequent exposure to CAK cells induced greater cytotoxicity than either treatment alone. Inclusion of soluble MICB significantly reduced cytotoxicity. CONCLUSION: Gemcitabine induced MICA/B expression in HepG2 cells, resulting in synergistic enhancement of the cytotoxic effects of NKG2D-high CAK cells. The combination of gemcitabine and CAK cells may have clinical therapeutic significance for HCC.
[Mh] Termos MeSH primário: Antimetabólitos Antineoplásicos/farmacologia
Carcinoma Hepatocelular/patologia
Desoxicitidina/análogos & derivados
Antígenos de Histocompatibilidade Classe I/biossíntese
Neoplasias Hepáticas/patologia
Monócitos Matadores Ativados/imunologia
Subfamília K de Receptores Semelhantes a Lectina de Células NK/imunologia
[Mh] Termos MeSH secundário: Carcinoma Hepatocelular/sangue
Carcinoma Hepatocelular/terapia
Linhagem Celular Tumoral/efeitos dos fármacos
Linhagem Celular Tumoral/imunologia
Células Cultivadas/efeitos dos fármacos
Terapia Combinada
Citotoxicidade Imunológica
Desoxicitidina/farmacologia
Citometria de Fluxo
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Antígenos de Histocompatibilidade Classe I/genética
Seres Humanos
Técnicas In Vitro
Interleucina-2/farmacologia
Neoplasias Hepáticas/sangue
Neoplasias Hepáticas/terapia
Muromonab-CD3/farmacologia
Proteínas Recombinantes/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimetabolites, Antineoplastic); 0 (Histocompatibility Antigens Class I); 0 (Interleukin-2); 0 (KLRK1 protein, human); 0 (MHC class I-related chain A); 0 (MICB antigen); 0 (Muromonab-CD3); 0 (NK Cell Lectin-Like Receptor Subfamily K); 0 (Recombinant Proteins); 0W860991D6 (Deoxycytidine); B76N6SBZ8R (gemcitabine)
[Em] Mês de entrada:1111
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110830
[St] Status:MEDLINE


  4 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21516291
[Au] Autor:Sipka S
[Ad] Endereço:3rd Department of Internal Medicine, University of Debrecen, Debrecen, Hungary. sipka@iiibel.dote.hu
[Ti] Título:Adenosine inhibits the release of arachidonic acid in activated human peripheral mononuclear cells. A proposed model for physiologic and pathologic regulation in systemic lupus erythematosus.
[So] Source:ScientificWorldJournal;11:972-80, 2011 Apr 19.
[Is] ISSN:1537-744X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the current work, the pathways are presented and reviewed showing how adenosine acts on the production and release of arachidonic acid (AA) in activated human monocytes by the involvement of various phospholipase A2 (PLA2) and protein kinase C (PKC) enzymes in physiological (normal) conditions and in a pathologic state in systemic lupus erythematosus (SLE). Two molecules of activated monocytes mainly determine the actual amounts of AA released: (1) interleukin-1 beta (IL-1 beta) increasing and (2) adenosine (Ado) suppressing this process. The AA production of monocytes mainly depends on two (IV and VI) types of PLA2 enzymes. PKC alpha phosphorylates the cytosolic, Ca2+-dependent and steroid-sensitive PLA2 (type IV), whereas PKC delta phosphorylates the Ca2+-independent PLA2 (type VI). By the suppression of IL-1 beta production in the activated human monocytes, adenosine can decrease the release of AA causing a diminished phosphorylation of both PKC isoenzymes. In SLE monocytes, the disease-specific decreased release of AA that we found earlier could be related to the decreased expression of PKC delta. These pathways are summarized in a proposed model.
[Mh] Termos MeSH primário: Adenosina/fisiologia
Ácido Araquidônico/metabolismo
Lúpus Eritematoso Sistêmico/metabolismo
[Mh] Termos MeSH secundário: Adenosina/química
Adenosina/metabolismo
Ácido Araquidônico/biossíntese
Ácido Araquidônico/fisiologia
Seres Humanos
Interleucina-1beta/metabolismo
Interleucina-1beta/fisiologia
Modelos Biológicos
Monócitos Matadores Ativados/metabolismo
Proteína Quinase C/metabolismo
Proteína Quinase C/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Interleukin-1beta); 27YG812J1I (Arachidonic Acid); EC 2.7.11.13 (Protein Kinase C); K72T3FS567 (Adenosine)
[Em] Mês de entrada:1201
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110426
[St] Status:MEDLINE
[do] DOI:10.1100/tsw.2011.88


  5 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21323569
[Au] Autor:Baron S; Finbloom J; Horowitz J; Bekisz J; Morrow A; Zhao T; Fey S; Schmeisser H; Balinsky C; Miyake K; Clark C; Zoon K
[Ad] Endereço:Cytokine Biology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
[Ti] Título:Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro.
[So] Source:J Interferon Cytokine Res;31(7):569-73, 2011 Jul.
[Is] ISSN:1557-7465
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We have previously reported that low concentrations of interferon (IFN)-activated monocytes exert near-eradicative cytocidal activity against low concentrations of several human tumor cells in vitro. In the present study, we examined 7 human tumor cell lines and 3 diploid lines in the presence or absence of 10 ng/mL IFNα2a and monocytes. The results confirmed strong cytocidal activity against 4 of 7 tumor lines but none against 3 diploid lines. To model larger in vivo tumors, we increased the target cell concentration and determined the concentration of IFNα2a and monocytes, required for cell death. We found that increasing the tumor cell concentration from 10- to 100-fold (10(5) cells/well) required an increase in the concentration of IFNs by over 100-fold and monocytes by 10-fold. High concentrations of monocytes could sometimes kill tumor or diploid cells in the absence of IFN. We may conclude that killing of high concentrations of tumor or diploid cells required high concentrations of monocytes that could sometimes kill in the absence of IFN. Thus, high concentrations of tumor cells required high concentrations of IFN and monocytes to cause near eradication of tumor cells. These findings may have clinical implications.
[Mh] Termos MeSH primário: Interferon-alfa/farmacologia
Monócitos Matadores Ativados/efeitos dos fármacos
Neoplasias/tratamento farmacológico
Neoplasias/imunologia
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Citotoxicidade Imunológica/efeitos dos fármacos
Cálculos da Dosagem de Medicamento
Seres Humanos
Monócitos Matadores Ativados/imunologia
Monócitos Matadores Ativados/metabolismo
Monócitos Matadores Ativados/patologia
Neoplasias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., INTRAMURAL
[Nm] Nome de substância:
0 (Ifna2 protein, mouse); 0 (Interferon-alpha)
[Em] Mês de entrada:1111
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110218
[St] Status:MEDLINE
[do] DOI:10.1089/jir.2010.0153


  6 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21070856
[Au] Autor:Kinnier CV; Martinu T; Gowdy KM; Nugent JL; Kelly FL; Palmer SM
[Ad] Endereço:Department of Medicine, Duke University Medical Center, 106 Research Drive, Building MSRB2 Room 2100B, Durham, NC 27710, USA.
[Ti] Título:Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant.
[So] Source:Transpl Immunol;24(2):83-93, 2011 Jan 15.
[Is] ISSN:1878-5492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Respiratory viral infections cause significant morbidity and increase the risk for chronic pulmonary graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT). Our overall hypothesis is that local innate immune activation potentiates adaptive alloimmunity. In this study, we hypothesized that a viral pathogen-associated molecular pattern (PAMP) alone can potentiate pulmonary GVHD after allogeneic HCT. We, therefore, examined the effect of pulmonary exposure to polyinosinic:polycytidylic acid (poly I:C), a viral mimetic that activates innate immunity, in an established murine HCT model. Poly I:C-induced a marked pulmonary T cell response in allogeneic HCT mice as compared to syngeneic HCT, with increased CD4+ cells in the lung fluid and tissue. This lymphocytic inflammation persisted at 2 weeks post poly I:C exposure in allogeneic mice and was associated with CD3+ cell infiltration into the bronchiolar epithelium and features of epithelial injury. In vitro, poly I:C enhanced allospecific proliferation in a mixed lymphocyte reaction. In vivo, poly I:C exposure was associated with an early increase in pulmonary monocyte recruitment and activation as well as a decrease in CD4+FOXP3+ regulatory T cells in allogeneic mice as compared to syngeneic. In contrast, intrapulmonary poly I:C did not alter the extent of systemic GVHD in either syngeneic or allogeneic mice. Collectively, our results suggest that local activation of pulmonary innate immunity by a viral molecular pattern represents a novel pathway that contributes to pulmonary GVHD after allogeneic HCT, through a mechanism that includes increased recruitment and maturation of intrapulmonary monocytes.
[Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/imunologia
Transplante de Células-Tronco Hematopoéticas
Imunidade Inata
Pneumopatias/imunologia
Pulmão/imunologia
Monócitos/imunologia
Poli I-C/imunologia
[Mh] Termos MeSH secundário: Imunidade Adaptativa
Animais
Complexo CD3
Linfócitos T CD4-Positivos/imunologia
Citometria de Fluxo
Camundongos
Camundongos Endogâmicos C57BL
Monócitos Matadores Ativados/imunologia
Mucosa Respiratória/imunologia
Infecções Respiratórias/virologia
Linfócitos T Reguladores/imunologia
Transplante Homólogo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (CD3 Complex); O84C90HH2L (Poly I-C)
[Em] Mês de entrada:1107
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101113
[St] Status:MEDLINE
[do] DOI:10.1016/j.trim.2010.11.004


  7 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:20124954
[Au] Autor:Hannani D; Gabert F; Laurin D; Sall M; Molens JP; Hequet O; Chaperot L; Plumas J
[Ad] Endereço:Inserm, U823, Immunobiologie et Immunotherapie des cancers, La Tronche, France.
[Ti] Título:Photochemotherapy induces the apoptosis of monocytes without impairing their function.
[So] Source:Transplantation;89(5):492-9, 2010 Mar 15.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Extracorporeal photopheresis (ECP) is a powerful therapy currently used to treat various hematological disorders as in graft versus host disease. Clinical data clearly demonstrate its efficacy and immunomodulation toward the pathogenic T cells. However, ECP mechanism of action is still poorly understood. Monocytes represent up to 30% of the total amount of treated cells and are known to play an important role in adaptive immunity. However, data from previous reports analyzing the effect of psoralen and UV-A irradiation (PUVA) on their functions are heterogeneous. In this study, we focused on the effect of PUVA on human monocytes functions in adaptive immunity. DESIGN AND METHODS: Purified human monocytes were treated in vitro by PUVA. We measured their kinetic of apoptosis after the treatment. We also determine whether their phenotype and functionalities were modified. Finally, we assessed the functionalities of PUVA-treated monocytes-derived dendritic cells (DC). RESULTS: PUVA treatment sentenced purified monocytes to die in 6 days and immediately altered their migratory capacities without impairing their ability of endocytosis. It also up-regulated co-stimulatory molecules and production of inflammatory cytokines on activation and consequently stimulated allogeneic or autologous T cells as efficiently as untreated monocytes. Moreover, PUVA-treated monocytes retained their ability to differentiate into fully functional DC that maturated and stimulated T cells as well as normal DC. CONCLUSIONS: Our data demonstrate that monocytes undergo apoptosis and loose a part of their migratory capacity after ECP and the surviving cell functionalities are not impaired, suggesting that monocytes have a minor effect on ECP-mediated immunomodulation.
[Mh] Termos MeSH primário: Apoptose
Monócitos/imunologia
Fotoquimioterapia/métodos
[Mh] Termos MeSH secundário: Imunidade Adaptativa
Apoptose/efeitos dos fármacos
Apoptose/efeitos da radiação
Técnicas de Cultura de Células/métodos
Morte Celular
Diferenciação Celular/efeitos dos fármacos
Movimento Celular
Células Cultivadas
Quimiotaxia de Leucócito/fisiologia
Células Dendríticas/efeitos dos fármacos
Células Dendríticas/imunologia
Células Dendríticas/efeitos da radiação
Seres Humanos
Imunofenotipagem
Monócitos/citologia
Monócitos/efeitos dos fármacos
Monócitos/fisiologia
Monócitos Matadores Ativados/citologia
Monócitos Matadores Ativados/efeitos dos fármacos
Monócitos Matadores Ativados/imunologia
Terapia PUVA/métodos
Fotoferese/métodos
Valores de Referência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1004
[Cu] Atualização por classe:141204
[Lr] Data última revisão:
141204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100204
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0b013e3181c6ffd3


  8 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19883528
[Au] Autor:Miller SC; Delorme D; Shan JJ
[Ad] Endereço:Department of Anatomy and Cell Biology, McGill University, Montreal, QC. sandra.miller@mcgill.ca
[Ti] Título:CVT-E002 stimulates the immune system and extends the life span of mice bearing a tumor of viral origin.
[So] Source:J Soc Integr Oncol;7(4):127-36, 2009.
[Is] ISSN:1715-894X
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:The present study evaluated the dose-related effects of CVT-E002, a proprietary extract of Panax quinquefolius (CV Technologies Inc., Edmonton, AB), in the treatment of a tumor of viral origin, that is, erythroleukemia, in mice. Three treatments including ingestion of 2, 40, and 120 mg/d were compared. The study revealed that the dose of 40 mg/d was particularly effective in stimulating cells mediating nonspecific immunity and extending the life span of tumor-bearing mice. This study represents the first in vivo demonstration of the anticancer efficacy of CVT-E002 in an animal model. CVT-E002 treatment significantly elevated the absolute numbers of natural killer cells and monocytes and reduced the number of tumor cells in the bone marrow and spleen. This study has shown that (1) approximately 30 to 50% of tumor-bearing mice administered CVT-E002 at a dose of 40 mg/d achieved a significantly extended life span, and (2) dosage is critical in producing these ameliorative effects.
[Mh] Termos MeSH primário: Vírus da Leucemia Murina de Friend
Células Matadoras Naturais/efeitos dos fármacos
Leucemia Eritroblástica Aguda/tratamento farmacológico
Monócitos Matadores Ativados/efeitos dos fármacos
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Animais
Medula Óssea/efeitos dos fármacos
Medula Óssea/imunologia
Células da Medula Óssea/efeitos dos fármacos
Células da Medula Óssea/imunologia
Leucemia Experimental
Masculino
Camundongos
Camundongos Endogâmicos DBA
Panax
Extratos Vegetais/administração & dosagem
Organismos Livres de Patógenos Específicos
Baço/citologia
Baço/efeitos dos fármacos
Baço/imunologia
Células Tumorais Cultivadas
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (COLD-fX); 0 (Plant Extracts)
[Em] Mês de entrada:1003
[Cu] Atualização por classe:091103
[Lr] Data última revisão:
091103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091104
[St] Status:MEDLINE


  9 / 69 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:18617991
[Au] Autor:Fogli M; Mavilio D; Brunetta E; Varchetta S; Ata K; Roby G; Kovacs C; Follmann D; Pende D; Ward J; Barker E; Marcenaro E; Moretta A; Fauci AS
[Ad] Endereço:Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
[Ti] Título:Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.
[So] Source:PLoS Pathog;4(7):e1000101, 2008 Jul 11.
[Is] ISSN:1553-7374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Understanding the cellular mechanisms that ensure an appropriate innate immune response against viral pathogens is an important challenge of biomedical research. In vitro studies have shown that natural killer (NK) cells purified from healthy donors can kill heterologous cell lines or autologous CD4+ T cell blasts exogenously infected with several strains of HIV-1. However, it is not known whether the deleterious effects of high HIV-1 viremia interferes with the NK cell-mediated cytolysis of autologous, endogenously HIV-1-infected CD4+ T cells. Here, we stimulate primary CD4+ T cells, purified ex vivo from HIV-1-infected viremic patients, with PHA and rIL2 (with or without rIL-7). This experimental procedure allows for the significant expansion and isolation of endogenously infected CD4+ T cell blasts detected by intracellular staining of p24 HIV-1 core antigen. We show that, subsequent to the selective down-modulation of MHC class-I (MHC-I) molecules, HIV-1-infected p24(pos) blasts become partially susceptible to lysis by rIL-2-activated NK cells, while uninfected p24(neg) blasts are spared from killing. This NK cell-mediated killing occurs mainly through the NKG2D activation pathway. However, the degree of NK cell cytolytic activity against autologous, endogenously HIV-1-infected CD4+ T cell blasts that down-modulate HLA-A and -B alleles and against heterologous MHC-I(neg) cell lines is particularly low. This phenomenon is associated with the defective surface expression and engagement of natural cytotoxicity receptors (NCRs) and with the high frequency of the anergic CD56(neg)/CD16(pos) subsets of highly dysfunctional NK cells from HIV-1-infected viremic patients. Collectively, our data demonstrate that the chronic viral replication of HIV-1 in infected individuals results in several phenotypic and functional aberrancies that interfere with the NK cell-mediated killing of autologous p24(pos) blasts derived from primary T cells.
[Mh] Termos MeSH primário: Linfócitos T CD4-Positivos/imunologia
Citotoxicidade Imunológica
Infecções por HIV/imunologia
Interleucina-2/imunologia
Células Matadoras Naturais/imunologia
Monócitos Matadores Ativados/imunologia
[Mh] Termos MeSH secundário: Linfócitos T CD4-Positivos/metabolismo
Linfócitos T CD4-Positivos/virologia
Proliferação Celular
Proteína do Núcleo p24 do HIV/imunologia
Infecções por HIV/sangue
Antígenos HLA-A/metabolismo
Antígenos HLA-B/metabolismo
Seres Humanos
Células Matadoras Naturais/metabolismo
Células Matadoras Naturais/virologia
Monócitos Matadores Ativados/metabolismo
Monócitos Matadores Ativados/virologia
Proteínas Recombinantes
Replicação Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HIV Core Protein p24); 0 (HLA-A Antigens); 0 (HLA-B Antigens); 0 (Interleukin-2); 0 (Recombinant Proteins)
[Em] Mês de entrada:0808
[Cu] Atualização por classe:140903
[Lr] Data última revisão:
140903
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080712
[St] Status:MEDLINE
[do] DOI:10.1371/journal.ppat.1000101


  10 / 69 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:18505060
[Au] Autor:Kimura H; Iizasa T; Ishikawa A; Shingyouji M; Yoshino M; Kimura M; Inada Y; Matsubayashi K
[Ad] Endereço:Division of Thoracic Diseases, Chiba Cancer Center, Chuo-ku, Chiba City, Chiba, Japan. dclak@chiba-cc.jp
[Ti] Título:Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients.
[So] Source:Anticancer Res;28(2B):1229-38, 2008 Mar-Apr.
[Is] ISSN:0250-7005
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The efficacy and toxicity of adjuvant chemo-immunotherapy using dendritic cells and activated killer cells are not clear in post-surgical primary lung cancer patients. PATIENTS AND METHODS: Pathologically diagnosed N2 lung cancer patients were selected for postsurgical adjuvant chemo-immunotherapy. The activated killer cells and dendritic cells (AKT-DC) obtained from tissue cultures of tumor-draining lymph nodes (TDLN) or from TDLN co-cultured with peripheral blood lymphocytes (TDLN-Pb) were used for the adoptive transfer of immunotherapy. The patients received 4 courses of chemotherapy along with immunotherapy every 2 months for 2 years. RESULTS: There were 31 N2 patients eligible for the study. Three cases were excluded because of refusal by the patients after 1-2 courses of immunotherapy. For the 28 cases treated, a total of 313 courses of immunotherapy were administered. The main toxicities were fever (78.0%), chill (83.4%), fatigue (23.0%) and nausea (17.0%) on the day of cell transfer. The 2- and 5-year survival rates were 88.9 % (95.9-81.9; 95% confidence interval, C.I.) and 52.9% (76.4-29.4; C.I.). CONCLUSION: Adoptive transfer of activated killer cells and dendritic cells from the tumor-draining lymph nodes of primary lung cancer patients is feasible and safe, and a large-scale multi-institutional study is necessary for evaluation of the efficacy of this treatment.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/terapia
Células Dendríticas/imunologia
Imunoterapia Adotiva/métodos
Neoplasias Pulmonares/terapia
Monócitos Matadores Ativados/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Carboplatina/administração & dosagem
Carcinoma Pulmonar de Células não Pequenas/imunologia
Carcinoma Pulmonar de Células não Pequenas/patologia
Quimioterapia Adjuvante
Feminino
Seres Humanos
Imunoterapia Adotiva/efeitos adversos
Neoplasias Pulmonares/imunologia
Neoplasias Pulmonares/patologia
Linfonodos/imunologia
Masculino
Meia-Idade
Estadiamento de Neoplasias
Paclitaxel/administração & dosagem
Prognóstico
Estudos Prospectivos
Taxoides/administração & dosagem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Taxoids); 15H5577CQD (docetaxel); BG3F62OND5 (Carboplatin); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:0806
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080529
[St] Status:MEDLINE



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde